<DOC>
	<DOCNO>NCT02905266</DOCNO>
	<brief_summary>This safety efficacy study different administration regimens nivolumab plus Ipilimumab subject previously untreated , unresectable metastatic melanoma .</brief_summary>
	<brief_title>A Safety Efficacy Study Multiple Administration Regimens Nivolumab Plus Ipilimumab Subjects With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Males Females , age 15 year â‰¥ age ( Except local regulation and/or institutional policy allow subject &lt; 18 year age participate ) Subjects must diagnose stage III or/and stage IV histologically confirm melanoma unresectable metastatic Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Subjects treat systemic anticancer therapy unresectable metastatic melanoma Subjects active brain metastasis leptomeningeal metastasis Subjects ocular melanoma Subjects active , know suspected autoimmune disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>